Activation of peroxisome proliferator-activated receptor (PPAR)-g by the thiazolidinedione (TZD) class of antidiabetic drugs elicits growth inhibition in a variety of malignant tumors. We clari®ed the eects of TZDs on growth of human non-small cell lung carcinoma (NSCLC) cells that express endogenous PPAR-g. Troglitazone and pioglitazone caused inhibition of cellular growth and induced apoptosis of NSCLC cells in a time-and dose-dependent manner. Subtraction cloning analysis identi®ed that troglitazone stimulated expression of the growth arrest and DNA-damage inducible (GADD)153 gene, and the increased expression of GADD153 mRNA was also con®rmed by an array analysis of the 160 apoptosis-related genes. Western blot analysis revealed that troglitazone also increased GADD153 protein levels in a time-dependent manner. Troglitazone did not stimulate GADD153 mRNA levels in undierentiated 3T3-L1 cells lacking PPAR-g expression, whereas its induction was clearly observed in dierentiated adipocytes expressing PPAR-g. Activity of the GADD153 promoter occurred in a NSCLC cell line in transient transcription assays and was signi®-cantly stimulated by troglitazone, although binding of PPAR/retinoid X receptor heterodimer was not detected in the promoter region in gel retardation assays. Inhibition of GADD153 gene expression by an antisense phosphorothionate oligonucleotide attenuated the troglitazone-induced growth inhibition. These ®ndings collectively indicated that activation of PPAR-g by TZDs could cause growth inhibition and apoptosis of NSCLC cells and that GADD153 might be a candidate factor implicated in these processes.
Introduction
The peroxisome proliferator-activated receptor (PPAR)-g is a member of the nuclear hormone receptor superfamily that regulates transcription of target genes in a ligand-dependent manner (Desvergne and Wahli, 1999) . PPAR-g binds to cis-acting DNA elements located within the promoter region of target genes by binding as heterodimers with the retinoid X receptor (RXR) (Desvergne and Wahli, 1999) . PPAR-g is highly expressed in adipocytes and functions as a master regulator of adipogenesis to promote adipocyte dierentiation and maturation (Tontonoz and Spiegelman, 1994; Lowell, 1999) . Expression of PPAR-g is not restricted to adipocytes, but is also found in a variety of other tissues, including the lung (Aperlo et al., 1995; Lambe and Tugwood, 1996) , in which PPAR-g might have diverse functions (Vamecq and Latrue, 1999 ). An example of the additional biological actions of PPAR-g was found in macrophages/monocytes, where ligand activation of PPAR-g inhibits production of in¯ammatory cytokines by antagonizing transcriptional activators (Ricote et al., 1998) . PPAR-g promotes uptake of oxidized low-density lipoprotein through transcriptional induction of the scavenger receptor . Although the natural ligand for PPAR-g is still under investigation, synthetic thiazolidinediones (TZDs) have been identi®ed as speci®c activators of PPAR-g (Forman et al., 1995; Lehmann et al., 1995) , and troglitazone and pioglitazone have been widely used for treatment of diabetic patients by enhancing the insulin sensitivity (Nolan et al., 1994; Olefsky, 2000) .
Somatic mutations of the PPAR-g gene were recently identi®ed in sporadic human colon cancers (Sarraf et al., 1999) . A chromosomal translocation, t(2 ; 3)(q13 ; p25) found in thyroid follicular carcinoma was reported to generate a fusion protein between PPARg and a thyroid-speci®c transcription factor, Pax8 (Kroll et al., 2000) . These ®ndings suggested that loss-of-function of PPAR-g might be directly involved in carcinogenesis and/or proliferation of a subset of human cancers. Furthermore, TZDs have been demonstrated to inhibit growth of several carcinoma cell lines that express endogenous PPAR-g (Tontonoz et al., 1997; Sarraf et al., 1998; Mueller et al., 1998; Keelan et al., 1999; Kubota et al., 1998; Elstner et al., 1998; Takahashi et al., 1999) . Activation of PPAR-g by TZDs could promote terminal dierentiation of human breast and colon cancers and myxoid liposarcoma in vivo and in vitro (Tontonoz et al., 1997; Sarraf et al., 1998; Mueller et al., 1998) . Cellular growth of breast, prostate, and gastric cancers and choriocarcinoma was also suppressed by TZDs through induction of apoptosis (Keelan et al., 1999; Kubota et al., 1998; Elstner et al., 1998; Takahashi et al., 1999) . Our recent ®ndings also revealed that troglitazone induced apoptosis of hamster pancreatic b-cell tumors (Ohtani et al., 1998) . On the basis of these ®ndings, it has been suggested that activation of the PPAR-g transcriptional pathway might be directly linked to growth inhibition of cancer cells via induction of terminal dierentiation and/or programed cell death. However, limited information is available regarding the molecular mechanism by which PPAR-g activation induces growth inhibition of carcinoma cells. Identi®cation of downstream target molecules that are responsible for these events might provide insights into the novel role of PPAR-g for cellular growth regulation tightly balanced by proliferation, dierentiation and apoptosis.
Using subtraction cloning and DNA array analyses, we sought to isolate genes whose expressions were regulated by PPAR-g activation in human non-small cell lung carcinoma (NSCLC) cells. We identi®ed a potential target gene whose expression change might be involved in the induction of growth inhibition and apoptosis of NSCLC cells by TZDs.
Results

Expression of the PPAR-g gene in NSCLC cells
To elucidate the eect of PPAR-g activators in lung carcinoma cells, we ®rst examined the expression of PPAR-g mRNA in four dierent human NSCLC cell lines. RT ± PCR analyses revealed ampli®cation of a PCR product in an expected length from both squamous (SQ-5 and EBC-1) and adenocarcinoma cells (ABC-1 and RERF-LC-OK) (Figure 1 ). The speci®c ampli®cation was con®rmed by sequencing the PCR products.
Growth inhibition of NSCLC cells by PPAR-g activators
We next examined whether activation of PPAR-g by the TZD class of antidiabetic drugs, troglitazone and pioglitazone aected growth of NSCLC cells using a MTT assay. The concentrations of TZDs used here were determined as clinically relevant in studies of peripheral insulin resistance (Nolan et al., 1994) . As shown in Figure 2, 75 M (means+s.e.m. from six samples). Pioglitazone also showed inhibition of cell growth, although the IC 50 value was approximately 10-fold higher than that of troglitazone ( Figure  2 ).
Induction of apoptosis by PPAR-g activation in lung carcinoma cells
We next determined whether apoptosis could contribute to inhibition of cellular growth of SQ-5 cells by PPAR-g activation. As shown in Figure 3A , increased numbers of apoptotic cells were detected by the treatment with 10 75 M troglitazone for 48 h using a TUNEL method (upper panels). Apoptotic cells representing chromatin aggregation was also apparent in the troglitazone-treated cells by Hoechst 33342 staining (lower panels). Figure 3B shows time-and dose-dependent increases in the amounts of DNA fragmentation in SQ-5 cells after troglitazone treatment. These ®ndings demonstrated that troglitazone elicited apoptosis of lung carcinoma cells.
Identification of candidate genes whose expressions were stimulated by troglitazone using a subtraction cloning assay
To elucidate the molecular mechanism underlying induction of cellular growth and apoptosis by PPARg activators in NSCLC cells, we attempted to identify the cellular genes whose expressions were upregulated by troglitazone using a PCR-based subtraction cloning assay. Among 596 clones partially sequenced, 383 clones showed signi®cant homology to functional genes in the nucleotide databases (EMBL and Genbank), and the remaining 213 clones showed no sequence homology to known genes. Of interest, 23 clones among the 383 clones matched to the known gene sequences were actually related to apoptosis. The remaining 22 clones were homologous to the nuclear hormone receptorrelated genes. Among 23 apoptosis-related genes, the Figure 1 Expression of the PPAR-g gene in lung carcinoma cells. An RT ± PCR analysis was performed to amplify the PPARg mRNA using total RNA isolated from four lung carcinoma cell lines. b-actin mRNA was also ampli®ed. The PCR products were electrophoresed in agarose gels and visualized by ethidium bromide staining Induction of GADD153 by PPAR-g g T Satoh et al genes frequently isolated were the growth arrest and DNA-damage inducible (GADD)153 gene (seven clones) and the murine tumor rejection gene (three clones). In addition, two clones showed sequence homology to the E2F-5 gene that is involved in cell cycle regulation.
Expression profiling of the PPAR-g -activated apoptosisrelated genes
To further identify and con®rm downstream target genes regulated by PPAR-g activation, we searched for a cDNA array representing 160 known transcripts and expressed sequence tags, all of which were apoptosisrelated genes. A gene was considered a candidate PPARg -target if it exhibited a change in expression level of at least twofold. Figure 4 is a scatter plot showing the intensity of each cDNA hybridized with¯uorescein-labeled probes derived from troglitazone-treated and control cells. Potential PPAR-g activated-apoptosis genes identi®ed by an array hybridization experiment were as follows; the extracellular signal-regulated kinase 3 (2.7-fold induction), induced myeloid leukemia cell dierentiation protein, MCL-1 (2.52-fold), E2F-5 (2.51-fold) and GADD153 (2.36-fold) genes. Among these genes, the latter two were identical to those identi®ed by the subtraction cloning assay.
Northern and Western blot analyses
To con®rm whether expression of the apoptosis-related genes identi®ed by subtraction cloning and microarray analyses were actually regulated by troglitazone, a series of Northern blot analyses was performed using the troglitazone-and non-treated lung carcinoma cell RNAs. Figure 5A shows induction of the GADD153 gene expression after 24 h treatment with troglitazone in SQ-5 cells. GADD153 mRNA was further increased after 48 h. As expected, troglitazone stimulated expression of the GADD153 gene in three other NSCLC cell lines ( Figure 5B ). In contrast, a modest increase in expression of the E2F-5 gene (approximately 1.3-fold) was observed after 48 h treatment with troglitazone ( Figure 5D ). To determine whether changes in GADD153 mRNA levels could correlate with those of the protein levels, we prepared nuclear extracts from troglitazone-or DMSO-treated SQ-5 cells and performed Western blot analysis for the GADD153 protein.
As shown in Figure 5C , GADD153 protein levels were increased by troglitazone treatment in a time-dependent manner. These ®ndings con®rmed that GADD153 mRNA and protein levels were increased by activation of PPAR-g.
Troglitazone did not induce GADD153 gene expression in a PPAR-g-deficient cell line
To test whether troglitazone could stimulate GADD153 mRNA expression through PPAR-g, Northern blot analysis was performed using a 3T3-L1 cell line. In this cell line, expression of PPAR-g occurs only after dierentiated to adipocytes by treatment with hormonal inducers (Kallen and Lazar, 1996) . As shown in Figure 6 , troglitazone did not increase GADD153 mRNA levels in undierentiated 3T3-L1 cells, but strongly induced its expression in dierentiated 3T3-L1 adipocytes. These ®ndings suggested that troglitazone might induce GADD153 expression through activation of PPAR-g.
Activation of the GADD153 promoter by troglitazone
PPAR-g is a ligand-dependent transcription factor that stimulates transcription of target genes by binding to the cis-acting response element in their promoter region. We, therefore, examined whether troglitazone could directly stimulate the promoter activity of the GADD153 gene using a transient transfection assay. Luciferase activity driven by the human GADD153 promoter occurred in SQ-5 cells that expressed endogenous PPAR-g, and signi®cant activation of the promoter activity by troglitazone was observed until 24 h-incubation ( Figure 7) . Cotransfection of the PPAR-g expression vector did not result in further activation, probably due to the high levels of expression of endogenous PPAR-g in this cell line ( Figure 7 ). Although a careful search for the nucleotide sequence of human GADD153 promoter (Park et al., 1992) revealed the absence of the completely matched direct repeat element separated by one bp spacer (DR1; AGGTCAxAGGTCA), a characteristic PPRE found in several PPAR-target genes (Desvergne and Wahli, 1999) ; two weakly matched DR1-like sequences were found at 528 bp (GGGTAAaACGGCG, underlines indicate nucleotides matched to the consensus DR1) and at 65 bp (AGGTTTtGGGGTC) upstream of the transcription start site (TSS). We, therefore, examined whether the PPAR/RXR heterodimer could directly bind these DR1-like elements using EMSA. In addition, we also evaluated PPAR/RXR binding to the DR element with no spacer (AGGGCAAGGCCA) positioned at 38 bp upstream of TSS. However, we could not detect apparent binding of the PPAR/RXR heterodimer to these elements, although PPAR/RXR could bind to the consensus DR1 element (data not shown). These ®ndings taken together suggested that PPAR-g might stimulate transcription of the GADD153 gene in the absence of direct DNA-binding.
Attenuation of troglitazone-induced growth inhibition by an antisense ODN against the GADD153 gene
To gain direct evidence that GADD153 caused growth inhibition of NSCLC cells by the PPAR activator, we lastly examined whether antisense inhibition of the GADD153 gene expression could aect growth inhibition of SQ-5 cells by troglitazone. We designed three dierent antisense ODNs corresponding to dierent portions of the GADD153 mRNA. The antisense or sense ODNs were transfected into SQ-5 cells by lipofection, and cellular growth in the presence or absence of troglitazone was measured using a MTT assay. As shown in Figure 8A , transfection of the antisense ODN-1 signi®cantly reduced troglitazoneinduced growth inhibition in a dose-dependent manner.
In contrast, other antisense ODNs did not show any eects. Moreover, three control sense ODNs did not aect growth inhibition by troglitazone. Transfection of the antisense ODN-1, but not the sense ODN-1 or mock transfection, clearly blocked troglitazone-induced expression of the GADD153 gene in SQ-5 cells ( Figure  8B ). These ®ndings indicated that antisense inhibition of the GADD153 gene could attenuate the growth inhibitory eect of a NSCLC cell line by troglitazone.
Discussion
The ®ndings of the present study demonstrated that TZDs induced growth inhibition and apoptosis of Figure 4 Scatter plot of expression pro®les of apoptosis-related genes. Poly(A) + RNAs isolated from troglitazone-or vehicletreated cells were reverse-transcribed in the presence of Cy5-or Cy3-dUTP, respectively. These cDNA probes were hybridized with a DNA array carrying the cDNAs of 160 apoptosis-related genes, and the intensity of the hybridization signals was detected with an array scanner (Keelan et al., 1999; Kubota et al., 1998; Elstner et al., 1998; Takahashi et al., 1999) . Troglitazone also increased apoptotic cell numbers in white adipose tissues of obese Zucker rats (Okuno et al., 1998) . However, the molecular mechanism underlying induction of growth inhibition and apoptosis by activation of PPAR-g remains unknown. Identi®cation of downstream target genes regulated by PPAR-g activation relevant to growth inhibition and apoptosis might provide insights into novel actions of PPAR-g in the regulation of cancer proliferation. While the present manuscript was being prepared, two independent groups reported that TZDs led to apoptosis of lung carcinoma cells (Tsubouchi et al., 2000; Chang and Szabo, 2000) . We have con®rmed their ®ndings and extended an attempt to identify downstream factors regulated by TZDs.
To identify potential target genes whose expressions were regulated by activation of PPAR-g in lung cancer cells, we employed two dierent methodologies, the subtraction cloning assay and microarray analysis. Among putative PPAR-g-activated target genes associated with growth inhibition and apoptosis, a reproducible induction was observed with the GADD153 gene. Northern blot analyses con®rmed these observation and stimulation of the GADD153 gene expression was similarly observed among four dierent types of NSCLC cells. In association with its mRNA induction, GADD153 protein levels were increased by troglitazone treatment. Moreover, introduction of an antisense ODN against the GADD153 gene into SQ-5 cells signi®cantly suppressed troglitazone-induced GADD153 gene expression as well as cell growth inhibition. TZD-induced inhibition of cellular proliferation was recently observed in mouse stem cells lacking PPAR-g (Palakurthi et al., 2001) . It was clearly demonstrated in the present study that troglitazoneinduced GADD153 gene expression was not observed in a cell line that lacks PPAR-g expression. These ®ndings, taken together, suggested that GADD153 might be a candidate factor directly involved in the PPAR-g transcriptional pathway to induce growth inhibition of NSCLC cells.
The GADD153 gene was originally isolated as a gene implicated in cellular responses to many forms of stress (Fornace et al., 1989) . GADD153, also known as CHOP (C/EBP homologous protein) (Ron and Habener, 1992) , is a basic leucine zipper transcription factor that belongs to a family of the CCAAT/ enhancer-binding proteins (C/EBPs) (Lekstrom-Himes and Xanthopoulos, 1998). Several lines of evidence indicated that GADD153 might be directly involved in the cellular apoptosis pathway. Intense stress such as hypoxia and hypoglycemia elicits cellular apoptosis, and cellular factors in response to these stresses have been divided into two groups based on their hypoxiainducible factor (HIF) 1a-dependency (Carmeliet et al., 1998) . The GADD153 gene belongs to the HIF1a-independent group (Carmeliet et al., 1998) . In leukemic cell lines, GADD153 mRNA was reported to increase in accordance with apoptosis induced by a topoisomerase II inhibitor (Eymin et al., 1997) . Ectopic expression of GADD153 into leukemic cells induced apoptosis in a p53-independent manner (Matsumoto et al., 1996) . Mouse embryonal ®broblasts prepared from the GADD153 knock-out mice were found to be resistant to apoptosis when challenged with agents that perturb endoplasmic reticulum function (Zinszner et al., 1998) . Interestingly, a chromosomal translocation, t (12; 16) produced a chimeric mRNA fusion transcript between the GADD153/CHOP gene and a RNAbinding protein, FUS/TLS in human myxoid liposarcoma (Crozat et al., 1993) . Overexpression of the FUS/ Figure 6 Troglitazone did not induce GADD153 gene expression in a PPAR-g-de®cient cell line. 3T3-L1 preadipocytes were cultured and dierentiated to adipocytes by insulin, dexamethazone and IBMX as described in Materials and methods. Undierentiated and dierentiated 3T3-L1 cells were treated with 50 mM troglitazone or DMSO for 24 h, and total RNA was isolated. Ten micrograms of RNA were subjected to Northern blot analysis for GADD153 mRNA . Taken together with the present ®ndings, these observations suggest that GADD153 plays a critical role in regulating cell growth and that TZD-stimulated GADD153 gene expression might have a direct connection with the induction of apoptosis of lung carcinoma cells. The present transfection studies performed in a NSCLC cell line showed that activation of the human GADD153 promoter (7954/+91) was modestly but signi®cantly stimulated by troglitazone. However, lack of consensus PPRE in the human GADD153 promoter as well as in the hamster GADD153 gene (Leuthy et al., 1990) suggested that PPAR-g might stimulate the GADD153 gene expression via an indirect mechanism. Recent studies demonstrated that PPAR could regulate gene transcription independent of DNA binding possibly through protein ± protein interactions with other transcription factors (Medvedev et al., 2001; Tolon et al., 1998) . Several transcription factors such as C/EBPb, activation transcription factors and activator protein-1 complex were reported to bind and regulate the GADD153 gene promoter (Wolfgang et al., 1997; Fawcett et al., 1999; Qiao et al., 2000; Ubeda and Habener, 2000) . PPAR-g activation may directly or indirectly modulate the function of these enhancer proteins, thereby increasing the GADD153 gene expression. Further studies are necessary to elucidate the molecular mechanisms of stimulation of the GADD153 gene by TZDs.
Materials and methods
PPAR-g activators
The synthetic PPAR-g ligands, troglitazone and pioglitazone were from Sankyo Co. (Osaka, Japan) and Takeda Chemical Co. (Tokyo, Japan), respectively. These compounds were dissolved in DMSO and diluted to appropriate concentrations with culture medium. SQ-5 cells were cultured in 100 mm dishes and an antisense ODN-1 or sense ODN-1 was transfected in a condition identical with (A). Mock transfection did not include ODNs. After 24 h-incubation with 10 and 100 mM troglitazone or DMSO, total RNA was isolated and subjected to Northern blot analysis for GADD153 gene. RNA loading was shown at the bottom by ethidium bromide staining of the gel. Positions of 28S and 18S ribosomal RNA are indicated Cell culture NSCLC cell lines including SQ-5, EBC-1, ABC-1 and RERF-LC-OK cells (the ®rst two cell lines derived from squamous cell carcinoma and the last two from adenocarcinoma) were obtained from the Japan Cancer Research Resources Bank (Tokyo, Japan) and Cell Resource Center for Biomedical Research Institute of Development, Aging and Cancer (Tohoku University, Sendai, Japan). Cells were grown in RPMI 1640 culture medium containing 10% fetal bovine serum (FBS) at 378C in a humidi®ed 5% CO 2 atmosphere.
Expression of the PPAR-g gene in NSCLC cells identified by reverse transcription-polymerase chain reaction (RT ± PCR)
Ten micrograms of total RNA isolated from lung carcinoma cells were reverse-transcribed using a MMLV reverse transcriptase and oligo(dT17) primer. PPAR-g mRNA was ampli®ed using a primer pair (sense primer, 5'-TCTTGAATTCAACGACCAAGTAAC-3', antisense primer, 5'-GCACGAATTCCGTGACAATCTGTC-3') corresponding to the ligand binding domain of PPAR-g (Elbrecht et al., 1996) . The PCR condition was as follows; denaturing at 948C for 1.5 min, annealing at 588C for 1 min and ampli®cation at 728C for 2 min for 35 cycles. The predicted size of the PCR product was 418 base pairs (bps). b-actin mRNA was also ampli®ed as an internal control using the same PCR conditions.
Cell growth assay
Cells were seeded to 5610 3 cells/well in 96 well plates and incubated in the presence or absence of TZDs, and cellular growth was measured by a calorimetric 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assay as described previously (Mosmann, 1983) . Cells treated with DMSO in parallel served as a control.
Detection of apoptotic cells
SQ-5 cells (5610
5 cells/dish) were cultured in the presence or absence of 10 74 M troglitazone for 2 days and were ®xed with 1% paraformaldehyde. The apoptotic cells were detected by the terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-biotin nick end labeling (TUNEL) using an Oncor in situ apoptosis detection kit (ApopTag, Gaithersburg, MD, USA). Nuclear changes were visualized by staining with 10 mM Hoechst 33342 and analysed using ā uorescence microscope with standard¯uorescence and emission ®lters.
Quantitative detection of DNA fragmentation
The amounts of cellular DNA fragmentation in the presence or absence of troglitazone were measured using a DNA fragmentation kit supplied by Boehringer-Mannheim GmbH (Germany) according to the manufacturer's protocol.
Subtraction cloning assay
The genes of NSCLC cells whose expressions were stimulated by troglitazone were identi®ed by a subtraction cloning procedure using a PCR-based cloning kit (Clontech Inc.) as described previously (Kameda et al., 1999) . Poly(A) + RNAs from SQ-5 cells (10 6 cells per dish) treated with 10 74 M troglitazone for 2 days or vehicle alone were prepared and reverse-transcribed to double-stranded cDNAs. These cDNAs were digested with RsaI, yielding short blunt-ended cDNAs. The RsaI-digested cDNAs from the troglitazone-treated cells were divided into two portions, and each cDNA pool was ligated with a dierent adapter (5'-CTAATACGACTCAC-TATAGGGCTCGAGCGGCCGCCCGGGCAGGT-3 and 5'-TGTAGCGTGAAGACGACAGAAAGGGCGTGGTG-CGGAGGGCGGT-3). Each adaptor-ligated cDNAs was hybridized with a 30-fold excess amount of the short and blunt-ended cDNAs with no adaptor derived from the DMSO-treated cells for 8 h at 728C. Hybridization solutions were subsequently combined and further incubated at 728C for 16 h to perform the second hybridization. After the second hybridization, a portion of the single-stranded cDNAs with each adapter at one end was annealed together to form double-stranded cDNAs which had dierent adapters at the 5' and 3' end. The cDNAs with such ends were ampli®ed by PCR using primers speci®c for each adapter sequence (5'-CTAATACGACTCACTATAGGGC-3' and 5'-TGTAGCG-TGAAGACGACAGAA-3'). A second PCR ampli®cation of the cDNAs was further performed using nested primers speci®c for each adapter sequence (5'-TCGAGCGGCCGCC-CGGGCAGGT-3' and 5'-AGGGCGT GGTGCGGAGGG-CGGT-3'). The resulting PCR products were separated by electrophoresis in a 1% agarose gel, and the PCR products ranging between 0.5 and 2.0 kilo-bps in length were puri®ed and subcloned into a pGEM-T vector (Promega) to construct a subtraction plasmid cDNA library. The plasmid library was transformed into E. Coli DH5 a and colonies were randomly isolated. Plasmid DNAs were prepared and the nucleotide sequences of insert cDNAs were determined using an automated DNA sequencer (Perkin-Elmer Model 377).
DNA array analysis
The poly(A) + RNAs were isolated from the troglitazone-or vehicle-treated cells under conditions similar to those described for the subtraction cloning assay. Using 1.0 mg of each poly(A) + RNA as a template and Cy5-or Cy3-dUTP as a¯uorescent labeling dye, the corresponding cDNA probe was synthesized by an AMV reverse transcriptase. As an internal control, the same amount of lambda poly(A) + RNA was mixed with each mRNA. The heat-denatured cDNA probes were hybridized to a DNA array (human Apoptosis CHIP, ver.1, Takara Biomedical Co., Tokyo, Japan) prehybridized with 100 mg/ml sermon sperm DNA. Hybridization was performed at 688C for 14 h followed by washing under stringent conditions, and hybridization signals were analysed using a GMS 418 array scanner.
Northern blot analysis
A full-length cDNA encoding the human GADD153 gene was ampli®ed by PCR using a human placenta cDNA library as a template. According to the reported sequence (Fornace et al., 1989) , the primer set was designed as follows; forward primer, 5'-AGAGACTTAAGTCTAAGGCAC-3'; reverse primer, 5'-ATAGAAAGTCACTTTAATAG-3'. A cDNA for the GADD153 gene in the predicted length of 895 bp was ampli®ed and subcloned into a pGEM-T vector. The nucleotide sequence was determined using an autosequencer. The full-length cDNA encoding E2F-5 was excised from the pcDNA3-E2F-5 (Sardet et al., 1995) (provided by Dr RA Weinberg) with XbaI and BamHI digestion and was subcloned into the XbaI/BamHI site of pGEM7Z (pGE-ME2F-5) (Promega). Twenty micrograms of total RNA isolated from lung carcinoma cells treated with troglitazone or DMSO were electrophoresed on a 1.2% agarose gel and transferred to a nylon membrane. The membrane was hybridized with a [ 32 P]-labeled complementary RNA (cRNA) probe for GADD153 or E2F-5 synthesized from pGEM-TGADD153 or pGEME2F5, respectively. Hybridization conditions were as previously described (Satoh et al., 1993) . Autoradiography was performed at 7808C with an intensifying screen.
Nuclear protein extracts and Western blot analysis
Nuclear protein extracts were prepared from SQ-5 cells treated with troglitazone or DMSO as previously described (Ren et al., 1998) . Protein concentrations were determined by Bradford's method. Ten micrograms of nuclear proteins were resolved on 10% polyacrylamide gels under denaturing conditions and transferred onto nitrocellulose membranes (Hybond ECL, Amersham Pharmacia Biotech). After incubation in a blocking buer (20 mM Tris-HCl (pH 7.6), 137 mM NaCl and 5% skimmed milk) for 1 h at room temperature, the membranes were incubated overnight at 48C with an anti-GADD153 mouse monoclonal antibody (B-3) (Santa Cruz). Following extensive washing, the membranes were incubated with a sheep anti-mouse Ig antibody for 1 h at room temperature, and GADD153 proteins were visualized with the ECL Plus Western blotting detection kit (Amersham).
Transient transfection and luciferase assay
A DNA fragment encoding the 5'-flanking region of the human GADD153 gene (7954 to +91) was ampli®ed by PCR from the GADD153CAT plasmid supplied by Drs Holbrook and Fornace (Fornace et al., 1989) , and ligated into a ®re¯y luciferase reporter vector (pA3Luc). The expression vector for human PPAR-g (pKCR2PPAR-g) was described previously (Monden et al., 1999) . Transient transfection was performed into SQ-5 cells cultured in 6-well plates by the calcium phosphate precipitation method using 1.67 mg of the reporter construct and/or 83 ng of the expression vector for PPAR-g/well as described previously (Ren et al., 1998; Satoh et al., 1996; Monden et al., 1999) . The total amounts of plasmids transfected into each plate were adjusted by adding an empty pKCR2 vector. Sixteen hours after transfection, cells were washed with PBS and incubated with MEM containing 10% FBS stripped with AG1-X8 resin (Bio-Rad) and activated charcoal to eliminate bioactive substances such as retinoids. The luciferase assay was carried out after incubation in the presence or absence of 10 75 M troglitazone for 24 h as described previously (Ren et al., 1998; Satoh et al., 1996) . The luciferase activities were normalized by protein concentrations measured by Bradford's method, and were expressed as light units per mg of protein as described previously (Ren et al., 1998; Satoh et al., 1996) .
Electrophoretic mobility shift assay (EMSA)
Human PPAR-g and RXR-g proteins were synthesized using an in vitro transcription coupled with translation system (Promega) from pKCR2PPAR-g and pKCR2RXR-g (Monden et al., 1999), respectively. The nucleotide sequence of the upper strand of the consensus PPAR response element (PPRE) probe was 5'-AGCTTCAGGTCAGAGGTCAGA-GAGCT-3' (underlines indicate the core half-site sequence). The double-stranded oligonucleotide was radiolabeled using a Klenow fragment of the DNA polymerase I, and EMSA was performed in conditions described previously (Ren et al., 1998; Satoh et al., 1996) .
Culture and induction of adipocyte differentiation of 3T3-L1 cells
3T3-L1 preadipocytes were maintained in Dulbecco's modi®ed Eagles medium (DMEM) with high glucose (12 mM) supplemented with 10% FBS (GIBCO BRL) and penicillin/ streptomycin. After con¯uency, dierentiation of 3T3-L1 preadipocytes was induced as previously described (Kallen and Lazar, 1996) by adding 10 mg/ml insulin, 1 mM dexamethazone and 0.5 mM 3-methyl-1-isobutylxanthine (SIGMA) for 2 days, and media were subsequently changed to DMEM containing 10 mg/ml insulin and 10% FBS. Thereafter, media were changed every 2 days until treatment with troglitazone. Troglitazone was added on day 6 after media were changed to the post-dierentiation medium. After 24 h-incubation with troglitazone or DMSO, total RNA was isolated from dierentiated and undierentiated 3T3-L1 cells and Northern blot analysis for GADD153 mRNA was performed as described above.
Experiments using antisense oligodeoxynucleotides against the GADD153 gene
Based on the nucleotide sequence of the human GADD153 cDNA (Fornace et al., 1989) , antisense phosphorothionate oligodeoxynucleotides (ODNs) and sense phosphorothionate ODNs were designed using prediction software for eective antisense sequences (Toagosei Co., Ltd., Tsukuba, Japan). The nucleotide sequence of antisense ODNs against the GADD153 gene were as follows; antisense ODN-1; 5'-CTGTTCTTTCTCCTTCATGC-3', antisense ODN-2; 5'-ACTTTCCTTTCATTCTCCTGTT-3', and antisense ODN-3; 5'-TCACTTTAATAGATAGGGACAGTAATAA-3'. The sense ODNs 1, 2 and 3 were exactly complementary to the antisense ODNs 1, 2 and 3, respectively. SQ-5 cells (4610 4 cells/well) were transfected with 1*4610 77 M of antisense or sense ODNs in parallel with 20 ml GenePOR-TER (Gene Therapy System, Inc., San Diego, USA) in serum-free medium at 378C for 4 h as described previously (Levy et al., 1991; Wagner, 1994) . Ten per cent of resin ± charcoal-treated FBS was added, and the cells were incubated for 24 h. After an additional incubation for 24 h in the presence or absence of 10 74 M troglitazone, cell growth was determined by a MTT assay. SQ-5 cells were cultured in 100 mm dishes and an antisense ODN-1 or sense ODN-1 was transfected in a condition identical above. After 24 hincubation with troglitazone or DMSO, total RNA was isolated and subjected to Northern blot analysis for GADD153 mRNA.
Statistical analysis
The signi®cance of dierences was determined by analysis of variance according to Duncan's multiple range test.
